Truist raises Exelixis stock target to $43 on Zanza optimism
Truist Securities increased its price target for Exelixis (NASDAQ:EXEL) shares to $43.00, up from the previous target of $42.00, while reaffirming a Buy rating on the stock. The new target represents ...
MedPage Today3m
Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...
Stifel maintains hold rating, $30 target on Exelixis stock
Stifel analysts maintained a Hold rating with a $30.00 price target on Exelixis stock (NASDAQ:EXEL), currently trading at $33.32 with a market capitalization of $9.5 billion. According to InvestingPro ...